RANBAXY RECEIVES TENTATIVE APPROVAL TO MARKET SUMATRIPTAN SUCCINATE TABLETS

Ranbaxy Laboratories Limited (RLL), announced today that the Company has received tentative approval from the U.S. Food and Drug Administration to manufacture and market Sumatriptan Succinate Tablets, 25 mg (base), 50 mg (base) and 100 mg (base). Total annual market sales for Sumatriptan Succinate Tablets were $857 million (+2.8%) (IMS – MAT: March 2005).

Sumatriptan Succinate Tablets (Imitrex®) Tablets are indicated for the acute treatment of migraine attacks with or without aura in adults.

“We are pleased to receive this tentative approval for Sumatriptan Succinate Tablets. This product represents a future opportunity for Ranbaxy and will be launched following final approval from the FDA that will further expand our growing portfolio of affordable generic product formulations ,” according to Jim Meehan, Vice President of Sales and Marketing for RPI, USA.

Ranbaxy Pharmaceuticals Inc. (RPI) based in Jacksonville, Florida, USA, is a wholly owned subsidiary of Ranbaxy Laboratories Limited, India’s largest pharmaceutical company. RPI is engaged in the sale and distribution of generic and branded prescription products in the U.S. healthcare system.

Ranbaxy Laboratories Limited, India's largest pharmaceutical company, manufactures and markets brand and generic pharmaceuticals and Active Pharmaceutical Ingredients. Ranbaxy's continued focus on R&D has resulted in several approvals in developed markets and significant progress in New Drug Discovery Research. Ranbaxy's foray into Novel Drug Delivery Systems has led to proprietary "platform technologies" resulting in a number of products under development. The Company is selling its products in over 100 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 44 countries and manufacturing operations in 7 countries.

*Imitrex® is a registered trademark of GlaxoSmithKline.